Enhancing Drug Discovery through in silico 360 Target Analysis
Date: 30 July | Time: 3PM London/10AM New York
Enhancing Drug Discovery through in silico 360 Target Analysis
Date: 30 July | Time: 3PM London/10AM New York
Already Registered?
If you have previously registered for this event, please login below:
Register your details belowA strategic approach to reducing late stage attrition in drug development
Almost 50% of late stage failures in drug development are reported to be target-dependent, majorly associated with efficacy and safety issues. Intrinsic characteristics of a target may result in candidate attrition during the drug development process. While there may be therapeutic benefits associated with the target, it might be hard to drug, requiring a very highly selective candidate that is difficult to obtain. Even if a high degree of selectivity is obtained, the target may lie in a biological network that could trigger unintended responses upon modulation. Therefore, identifying the right target early is critical for ensuring the success of your program.
We have developed an in silico 360° analysis approach towards solving this challenge, by integrating available information and informatics-based insight to arrive at a careful advancement strategy during early discovery phase. In this webinar, we will share some insights on designing a decision-making algorithm for selecting the right drug target, and also demonstrate the value of in silico target analyses with supporting case-studies.
Presented by
Dr. Sonali Das,
Head – Syngene Target Diligence Services
Dr. Sonali Das leads Target Diligence services at Syngene. Dr. Das has completed a Ph.D. in cellular immunology and a postdoctoral fellowship in molecular virology from the University of California, Santa Barbara. She brings to the table 25+ years of research experience in frontier areas of science that interface chemistry and biology.
Key Learning Objectives
- If you are looking for cost effective ways to reduce drug target attrition, comprehensive in silico assessment is of definite interest. Join our webinar to gain insights into a practical strategy for 360° target analysis.
Audience
- Head of Drug Discovery
- Head of Bioinformatics
- Director of Drug Discovery
- Research Director
- Global Category Manager Drug Discovery
- Head of Oncology Research
- Vice President – Drug Discovery
- Head of Translational Research
- Head of Research informatics
- Chief Scientific Officer
- Head of Chemistry
- Head of Biology